Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study

Vincenzo Gennusa; Calogero Saieva; Richard M. Lee-Ying; Pier Vitale Nuzzo; Gian Paolo Spinelli; Elisa Zanardi; Giuseppe Fotia; Sabrina Rossetti; Loana Bueno Valenca; Anna Patrikidou; Livia Andrade; Ricardo Pereira Mestre; Giuseppe Fornarini; Giuseppe Procopio; Daniele Santini; Christopher Sweeney; Daniel Yick Chin Heng; Ugo De Giorgi; Antonio Russo; Edoardo Francini

doi:10.1200/JCO.2023.41.6_suppl.166

Back

Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study

Abstract

Open access

Peer reviewed

Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study

Vincenzo Gennusa, Calogero Saieva, Richard M. Lee-Ying, Pier Vitale Nuzzo, Gian Paolo Spinelli, Elisa Zanardi, Giuseppe Fotia, Sabrina Rossetti, Loana Bueno Valenca, Anna Patrikidou, …

Journal of clinical oncology, Vol.41(6_suppl), pp.166-166

02/20/2023

DOI: 10.1200/JCO.2023.41.6_suppl.166

Files and links (1)

url

https://doi.org/10.1200/JCO.2023.41.6_suppl.166View

Published (Version of record) Open Access

Abstract

166 Background: About 2/3 of all prostate cancer (PCa) deaths occur in patients aged ≥75, who are frequently diagnosed with advanced PCa. ARSi abiraterone acetate (AA) and enzalutamide (E) are the most common 1 st line Rx for patients with mCRPC. Yet, the optimal treatment sequence for the elderly ≥75 after ARSi failure is still unclear. Methods: Using available medical records, patients aged ≥75 who started ARSi as 1 st line Rx for mCRPC within January 2015 - April 2019 and, upon progression, 2 nd line alternative ARSi or D were identified from the IRB approved hospital registries of 10 centers in Europe, North and South America. Patients were categorized by type of 2 nd line Rx for mCRPC into cohorts AA/E and D. Primary endpoints were overall survival (OS) from 1 st line AA/E start, OS and radiographic progression-free survival (rPFS) from 2 nd line Rx start, and safety. The Kaplan Meier method was used to calculate endpoint distributions and medians (95% CI). Results: Of the 122 patients identified, 57 (46.7%) had AA/E and 65 (53.3%) D, as 2 nd line Rx for mCRPC. Median follow-up was 26.3 months (95% CI, 23.1-27.9 months). Cohort AA/E tended to be older (81 vs 78 years; p=0.001) and with high-volume disease (45.5% vs 25.0%; p=0.022) compared to cohort D. No significant difference in OS from 1 st line ARSi onset and OS or rPFS from 2 nd line Rx start was found between the 2 cohorts. Cohort AA/E had longer rPFS than cohort D, albeit not significant (18.5 vs 12.0 months; p=0.13). Rates of adverse events (AEs) of any grade (42.1 vs 53.8; p=0.21) and AEs of grade ≥3 (19.3% vs 18.5%; p=1.0) did not show significant differences between the 2 cohorts. Conclusions: Within the limitations of small cohorts and retrospective design, treatment sequences with 2 nd line AA/E or D after failure of 1 st line alternative ARSi for mCRPC showed similar efficacy and safety in the elderly ≥75 years old.

Details

Title: Subtitle: Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study
Creators: Vincenzo Gennusa - Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo
Calogero Saieva - Cancer Risk Factors and Lifestyle Epidemiology Unit – ISPRO, Firenze, Italy
Richard M. Lee-Ying - Tom Baker Cancer Centre, Calgary, AB, Canada
Pier Vitale Nuzzo - Cornell University
Gian Paolo Spinelli - Department of Medico-Surgical Sciences and Biotechnologies, Oncology Unit, Santa Latina, Italy
Elisa Zanardi - Ospedale Policlinico San Martino
Giuseppe Fotia - Fondazione IRCCS Istituto Nazionale dei Tumori
Sabrina Rossetti - Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Loana Bueno Valenca - D’Or Institute for Research and Education
Anna Patrikidou - Institut Gustave Roussy
Livia Andrade - D’Or Institute for Research and Education
Ricardo Pereira Mestre - Istituto Oncologico della Svizzera Italiana
Giuseppe Fornarini - Ospedale Policlinico San Martino
Giuseppe Procopio - Fondazione IRCCS Istituto Nazionale dei Tumori
Daniele Santini - Università Campus Bio-Medico
Christopher Sweeney - Harvard University
Daniel Yick Chin Heng - University of Calgary
Ugo De Giorgi - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Antonio Russo - University of Palermo
Edoardo Francini - Department of Experimental and Clinical Medicine, Firenze, Italy
Resource Type: Abstract
Publication Details: Journal of clinical oncology, Vol.41(6_suppl), pp.166-166
DOI: 10.1200/JCO.2023.41.6_suppl.166
ISSN: 0732-183X
eISSN: 1527-7755
Number of pages: 1
Language: English
Date published: 02/20/2023
Academic Unit: Internal Medicine
Record Identifier: 9985223630402771

Metrics

1 Record Views